Question: is this a 2) strong advice, 1) weak advice 0) no advice?

TWILIGHT is the largest study to date that is specifically designed and powered to demonstrate reductions in bleeding with ticagrelor monotherapy versus ticagrelor plus ASA beyond 3 months post-procedure in a high-risk PCI population treated with DES.
user
This is no advice
assistant